BHMP
PCRX icon

Bardin Hill Management Partners’s Pacira BioSciences PCRX Stock Holding History

Bardin Hill Management Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-256
Closed -$24K – 114
2014
Q2 		$24K Buy
+256
New +$19.5K ﹤0.01% 98

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bardin Hill Management Partners's PCRX Position: Q3 2014 in Review

Bardin Hill Management Partners sold out of Pacira BioSciences (PCRX) in Q3 2014, closing a stake of 256 shares — an estimated $24K sold.

Bardin Hill Management Partners first reported a position in PCRX in Q2 2014 and held it in 1 quarter. The position peaked at $24K in Q2 2014. 208 funds tracked by Wall St. Rank hold PCRX as of Q3 2014.

  • Bardin Hill Management Partners reported no remaining Pacira BioSciences position as of Q3 2014 after selling out during the quarter.
  • Bardin Hill Management Partners sold 256 Pacira BioSciences shares in Q3 2014, an estimated $24K.
  • Bardin Hill Management Partners first reported a position in Pacira BioSciences in Q2 2014 and held it in 1 quarter.
  • Bardin Hill Management Partners's Pacira BioSciences position peaked at $24K in Q2 2014.
  • 208 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2014.

Based on Bardin Hill Management Partners's 13F filing for Q3 2014, filed 14 Nov 2014.